Evidence map›Paper›PMID 39317182›Full record

Trial reportThe American journal of tropical medicine and hygiene2024

Cause-Specific Mortality among Infants in a Randomized Controlled Trial of Azithromycin Compared to Placebo for Prevention of Mortality.

Mamadou Ouattara, Ali Sié, Mamadou Bountogo, Valentin Boudo, Thierry Ouedraogo, Clarisse Dah, Elodie Lebas, Huiyu Hu, Aimee Lansdale, Ian Fetterman and 3 more

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The American journal of tropical medicine and hygiene, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Mamadou OuattaraCentre de Recherche en Santé de Nouna, Nouna, Burkina Faso.
Ali SiéCentre de Recherche en Santé de Nouna, Nouna, Burkina Faso.
Mamadou BountogoCentre de Recherche en Santé de Nouna, Nouna, Burkina Faso.
Valentin BoudoCentre de Recherche en Santé de Nouna, Nouna, Burkina Faso.
Thierry OuedraogoCentre de Recherche en Santé de Nouna, Nouna, Burkina Faso.
Clarisse DahCentre de Recherche en Santé de Nouna, Nouna, Burkina Faso.
Elodie LebasFrancis I. Proctor Foundation, University of California, San Francisco, San Francisco, California.
Huiyu HuFrancis I. Proctor Foundation, University of California, San Francisco, San Francisco, California.
Aimee LansdaleDepartment of Epidemiology & Biostatistics, University of California, San Francisco, San Francisco, California.
Ian FettermanFrancis I. Proctor Foundation, University of California, San Francisco, San Francisco, California.
Benjamin F ArnoldFrancis I. Proctor Foundation, University of California, San Francisco, San Francisco, California.
Thomas M LietmanFrancis I. Proctor Foundation, University of California, San Francisco, San Francisco, California.
Catherine E OldenburgFrancis I. Proctor Foundation, University of California, San Francisco, San Francisco, California.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although community randomized trials have found a reduction in all-cause child mortality in communities receiving mass azithromycin distribution compared with placebo, individually randomized trials have not found similar protective effects. If a direct effect of azithromycin for prevention of child mortality exists, it is likely due to reduction in infectious mortality. Here, we assessed cause-specific mortality in a large randomized controlled trial of azithromycin administered during well-infant visits in Burkina Faso for prevention of mortality. Among 32,877 enrolled infants, the most common causes of death by 6 months of age were malaria, acute respiratory infections, and diarrheal disease. We found no evidence of a difference in the distribution of cause of death by randomized treatment assignment (P = 0.42) or in any infectious-specific cause of death. The results of this analysis are consistent with no direct effect of azithromycin on infant mortality when administered during well-infant visits.

Indexed as

Anti-Bacterial AgentsAzithromycinInfant MortalityBurkina FasoCause of DeathFemaleHumansInfantInfant, NewbornMalariaMaleRespiratory Tract InfectionsAnti-Bacterial AgentsAzithromycin

Identifiers

PMID39317182
PMCPMC11619516

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.